On June 3, 2021 Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", reported a poster presentation on the safety and efficacy of PRV111 in patients with early-stage Head and Neck Squamous Cell Carcinoma (HNSCC). PRV111 is an anticancer topical patch that allows for locoregional treatment (Press release, Privo Technologies, JUN 3, 2021, View Source [SID1234583484]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation will be available at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting being held June 4-8, 2021.

Topical cancer treatment developed by Privo Technologies
Topical cancer treatment developed by Privo Technologies
It can be viewed by registered participants throughout the conference via the ASCO (Free ASCO Whitepaper) website.

The details of the poster presentation are as follows:

Title: A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC)

Speaker: Nishant Agrawal, M.D.

Poster Session: Head and Neck Cancer

Date and Time: June 4, 2021. Available for on-demand viewing beginning at 9:00 a.m. ET

Abstract Number: 6056